USA - NASDAQ:FBIO - US34960Q3074 - Common Stock
ChartMill assigns a Buy % Consensus number of 82% to FBIO. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-08-21 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-03-11 | Roth MKM | Reiterate | Buy -> Buy |
| 2024-11-18 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-07-19 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-06-20 | Cantor Fitzgerald | Reiterate | Overweight |
| 2024-05-16 | Roth MKM | Reiterate | Buy -> Buy |
| 2024-03-19 | Alliance Global Partners | Initiate | Buy |
| 2024-03-15 | Roth MKM | Reiterate | Buy |
| 2023-11-29 | Roth MKM | Maintains | Buy -> Buy |
| 2023-08-15 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023-05-16 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2023-04-06 | Benchmark | Reiterate | Speculative Buy |
| 2022-08-04 | Ladenburg Thalmann | Initiate | Buy |
| 2022-07-14 | B. Riley Securities | Maintains | Buy |
| 2021-04-20 | Roth Capital | Maintains | Buy |
9 analysts have analysed FBIO and the average price target is 11.22 USD. This implies a price increase of 346.58% is expected in the next year compared to the current price of 2.5124.
The consensus rating for FORTRESS BIOTECH INC (FBIO) is 82.2222 / 100 . This indicates that analysts generally have a positive outlook on the stock.
The number of analysts covering FORTRESS BIOTECH INC (FBIO) is 9.